NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone781-890-9989
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.09 million
Profitability
Miscellaneous
Employees42
Next Earnings Date10/17/2019 (Confirmed)
OptionableNot Optionable
Neurometrix (NASDAQ:NURO) Frequently Asked Questions
What is Neurometrix's stock symbol?
Neurometrix trades on the NASDAQ under the ticker symbol "NURO."
When did Neurometrix's stock split? How did Neurometrix's stock split work?
Neurometrix's stock reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.
How were Neurometrix's earnings last quarter?
Neurometrix Inc (NASDAQ:NURO) posted its quarterly earnings results on Wednesday, October, 17th. The medical device company reported $0.15 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.34. The medical device company had revenue of $3.67 million for the quarter. Neurometrix had a negative return on equity of 17.31% and a negative net margin of 23.52%. View Neurometrix's Earnings History.
When is Neurometrix's next earnings date?
What price target have analysts set for NURO?
1 brokers have issued 12-month target prices for Neurometrix's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Neurometrix's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1,460.5% from the stock's current price. View Analyst Price Targets for Neurometrix.
What is the consensus analysts' recommendation for Neurometrix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurometrix.
Has Neurometrix been receiving favorable news coverage?
News coverage about NURO stock has trended very negative on Thursday, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurometrix earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Neurometrix.
Are investors shorting Neurometrix?
Neurometrix saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 129,600 shares, a drop of 12.6% from the August 30th total of 148,200 shares. Based on an average daily volume of 115,700 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.4% of the company's shares are short sold. View Neurometrix's Current Options Chain.
Who are some of Neurometrix's key competitors?
Some companies that are related to Neurometrix include DarioHealth (DRIO), Lianluo Smart (LLIT), Hancock Jaffe Laboratories (HJLI), Obalon Therapeutics (OBLN), Dynatronics (DYNT), Valeritas (VLRX), Presbia (LENS), Sintx Technologies (SINT), Avinger (AVGR), CELLECT BIOTECH/S (APOP), Invivo Therapeutics (NVIV), Calmare Therapeutics (CTTC), Cytori Therapeutics (CYTX), Encision (ECIA) and Cytocore (MDIT).
What other stocks do shareholders of Neurometrix own?
Who are Neurometrix's key executives?
Neurometrix's management team includes the folowing people:
- Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)
- Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)
- Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)
- Mr. Michael J. MacDonald, Sr. VP of Commercial Operations & GM of Diagnostics
- Dr. Xuan Kong Ph.D., Chief Data Scientist
How do I buy shares of Neurometrix?
Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Neurometrix's stock price today?
One share of NURO stock can currently be purchased for approximately $0.32.
How big of a company is Neurometrix?
What is Neurometrix's official website?
How can I contact Neurometrix?
Neurometrix's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]
MarketBeat Community Rating for Neurometrix (NASDAQ NURO)
MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.
